VSPI
Trial Sponsored by:
NHS Greater Glasgow and Clyde
Investigators
Sponsor
- NHS Greater Glasgow and Clyde
Chief Investigator
Co-Investigator
Trial Project Manager
Trial Summary
VSPI: Markers and Mediators of Angiogenesis Inhibitor-Induced Vascular and Myocardial Toxicity: Prospective Study in Patients with Cancer
Advancements in cancer treatments in recent years have led to increased survival for many patients. Vascular endothelial growth factor-signalling pathway inhibitors (VSPIs) have accounted for some of this success and are now used in a range of malignancies. However, VSPIs are associated with cardiovascular toxicities including hypertension and heart failure.
The aims of this study are to characterise the vascular and myocardial effects of VSPIs at a macro- and microvascular level and to identify the mechanisms underlying these cardiovascular toxicities in order to identify pathophysiologically-targeted treatments.
Patient Recruitment
Recruitment status: Completed